The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 671-682 , October 2008

Host immune responses to rhinovirus: Mechanisms in asthma

  • John T. Kelly, MD
    • ,
  • William W. Busse, MD

      Affiliations

    • Corresponding Author InformationReprint requests: William W. Busse, MD, University of Wisconsin School of Medicine and Public Health, Department of Allergy and Clinical Immunology, J5/219 CSC, Box 2454, 600 Highland Ave, Madison, WI 53792.

Received 10 July 2008 ,Revised 15 August 2008 ,Accepted 18 August 2008.

  • Image Result

    EC response to rhinovirus infection. ECs secrete cytokines that attract neutrophils, eosinophils, and lymphocytes. Macrophages may be infected in part by rhinovirus released from the epithelium.

    EC response to rhinovirus infection. ECs secrete cytokines that attract neutrophils, eosinophils, and lymphocytes. Macrophages may be infected in part by rhinovirus released from the epithelium.

  • Image Result

    Immune cell response to rhinovirus. Innate immune response from macrophages includes secretion of cytokines, which recruit additional innate and adaptive immune cell responses. ECP, Eosinophilic catio

    Immune cell response to rhinovirus. Innate immune response from macrophages includes secretion of cytokines, which recruit additional innate and adaptive immune cell responses. ECP, Eosinophilic cationic protein; EDN, eosinophil-derived neurotoxin.

  • Image Result
    Consequences of immune response to rhinovirus and altered airway responses in asthma.

    Consequences of immune response to rhinovirus and altered airway responses in asthma.

  • Image Result
    Antiviral response to rhinovirus in a healthy subject versus a subject with asthma.

    Antiviral response to rhinovirus in a healthy subject versus a subject with asthma.

  • Image Result
    Interface and interactions between antirhinovirus therapeutic agents and regulation of the immune response to rhinovirus. Experimental agents in boldface; proposed therapies in italics.

    Interface and interactions between antirhinovirus therapeutic agents and regulation of the immune response to rhinovirus. Experimental agents in boldface; proposed therapies in italics.

 (Supported by an educational grant from Merck & Co., Inc.)

 Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, William T. Shearer, MD, PhD, and Donata Vercelli, MD

 Supported by National Institutes of Health–National Heart, Lung, and Blood Institute grant no. HL069116 and National Institutes of Health–National Institute of Allergy and Infectious Diseases grant no. T32 AI007635.

 Terms in boldface and italics are defined in the glossary on page 672.

PII: S0091-6749(08)01506-6

doi: 10.1016/j.jaci.2008.08.013

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 671-682 , October 2008

Article Tools

* Image Usage & Resolution